CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 21, 2011
Result type: Reports
Project Number: SR0257-000
Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Therapeutic Area: Atrial fibrillation, stroke prevention

Indications: Atrial fibrillation, stroke prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 19, 2012

Recommendation Type: List with clinical criteria and/or conditions